Or hand-foot syndrome.

The main investigator leading the project at international level can be Dr. A. Awada from the Jules Bordet Institute ( .. Advancell initiates ATH008 phase IIb study for hand-foot syndrome – Advancell offers announced the initiation of a clinical stage IIb research of its treatment ATH008 for palmar-plantar erythrodysesthesia syndrome, or hand-foot syndrome, a painful side-effect of chemotherapy. This treatment could possibly be available available by the end of 2015 or beginning of 2016 – Hand-foot syndrome is a cutaneous reaction involving inflammation, peeling, blisters and extreme discomfort on the palms of hands or the soles of feet.Case Report The patient is an 18-year-old, adopted white woman who presented at age 15 years with absent breast development, primary amenorrhea, and intermittent lower abdominal pain. The individual provided written consent for this scholarly study, which was approved by the Georgia Regents University Human being Assurance Committee. At the age of 17 years 9 a few months, the patient’s height was 162.6 cm, her weight was 44 kg, and her body-mass index was 16.6. She acquired Tanner stage 1 breast development and Tanner stage 4 pubic hair . She had serious facial acne. At the time of presentation, laboratory research revealed a serum estradiol degree of 3500 pg per milliliter , a luteinizing hormone level of 9.6 mIU per milliliter , a follicle-stimulating hormone level of 6.7 mIU per milliliter , and a normal female karyotype .